Healthcare forecasters might assume that because of demographics, heart disease would be a leading cause of increased demand for hospital services-and, therefore, healthcare costs.
Surprisingly, however, cardiac disease and specifically heart attacks, have been the second-fastest declining hospitalization since 2003, according to one industry expert.
"This is occurring despite an aging population and more patients being diagnosed with heart diseases," says Kaveh Safavi, MD, JD, chief medical officer, Thomson Healthcare. "Other research suggests that long-term population treatment of risk factors for heart disease and treatment of newly diagnosed heart disease leads to stable heart disease that does not result in hospital stays-but does consume outpatient resources."
While the cardiac category is still an important condition in absolute terms relative to costs and hospital admissions, its relative position is declining. "Medical conditions such as infection are becoming increasingly important causes of hospitalization, as are joint replacements," he says. "We also have found that more patients in the hospital had heart disease in 2006 versus 2003, but that is not the reason for their hospitalizations."
The increasing rate of hospitalization for kidney disease, which has not been widely understood, might hold the biggest surprise. "In absolute terms, kidney disease is not yet a large part of the hospitalization picture, but some research has shown that it will be the fastest growing disease between now and 2025," Dr. Safavi says. "The United States has a real shortage of kidney specialists given the increasing demand.
"Population trends alone do not predict demand on future cost," Dr. Safavi adds. "We often think about technology as adding cost, but we may have evidence that in the long run, changing the natural history of diseases will change the cost and demand curves, also."
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen